Freshfields Advised AbbVie on Its Collaboration with Iambic to Accelerate AI-Driven Drug Discovery

Freshfields advised AbbVie on its multi-year collaboration with Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience, and oncology. AbbVie and Iambic will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates.

Under the terms of the collaboration, Iambic will receive an upfront payment and is eligible to receive success-based milestone payments and tiered royalties on net sales from products generated from the collaboration.

The Freshfields team was led by Partners Jeff Jay and Kristen Riemenschneider and included Associates Jimmy Cao, Shannon O’Hara, Wolfgang Paulson and Yungjee Kim; Partner Menachem Kaplan advised on software and technology matters; and Partner Mary Lehner, Senior Associate Kaylynn Moss and Associate Sean Norick Long advised on antitrust matters.